CAPRICOR THERAPEUTICS, INC.

Listed Company

CAPRCIK 0001133869NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-105.04M

Total Assets

$355.95M

Equity

$305.79M

Shares Out

57.51M

Op. Cash Flow

$-69.81M

Business

CAPRICOR THERAPEUTICS, INC. is a clinical-stage biotechnology company developing transformative cell and exosome-based therapeutics focused primarily on Duchenne muscular dystrophy (DMD) and other high unmet-need diseases. Its main products and platforms include deramiocel, an allogeneic cardiosphere-derived cell therapy, and the StealthX™ engineered exosome platform for vaccines and therapeutics. Key business activities comprise clinical development, manufacturing (CMC) and licensing collaborations, including partnerships for distribution and clinical trials. Capricor targets the United States, Japan and Europe through distribution agreements and strategic collaborators such as Nippon Shinyaku and U.S. government and academic partners.

Summary from filing dated 2025-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0	22	25	3	244,898
TOTAL REVENUE	0	22	25	3	244,898
Research and development	84	50	36	22	14
General and administrative	24	15	13	10	8
TOTAL OPERATING EXPENSES	108	65	49	32	21
LOSS FROM OPERATIONS	−108	−43	−24	−30	−21
Other income	45,421	7,471	67,657	190,582	548,207
Investment income	6	2	2	521,535	57,460
Interest expense	−3	0	—	—	—
Loss on disposal of fixed assets	−157,519	−112,805	−6,041	−34,266	−7,905
TOTAL OTHER INCOME (EXPENSE)	3	2	2	677,851	915,922
LOSS BEFORE INCOME TAXES	−105	−40	—	—	—
(Provision for) benefit from income taxes	−1,600	−1,600	—	—	—
NET LOSS	−105	−40	−22	−29	−20
Net unrealized gain (loss) on marketable securities	−743,801	791,142	130,569	105,244	0
COMPREHENSIVE LOSS	−106	−40	−22	−29	−20
Net loss per share, basic (in dollars per share)	−2.26	−1.15	−0.83	−1.18	−0.87
Net loss per share, diluted (in dollars per share)	−2.26	−1.15	−0.83	−1.18	−0.87
Weighted average number of shares, basic (in shares)	46	35	27	25	23
Weighted average number of shares, diluted (in shares)	46	35	27	25	23

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-03-31
Cash and cash equivalents	288	11	15	10	—
Marketable securities	30	140	—	—	—
Receivables	59,167	10	10	547,580	—
Prepaid expenses and other current assets	5	2	995,776	919,892	—
TOTAL CURRENT ASSETS	323	163	51	43	—
PROPERTY AND EQUIPMENT, net	18	6	6	5	—
Lease right-of-use assets, net	14	1	2	2	—
Other assets	1	221,700	268,172	268,172	—
TOTAL ASSETS	356	170	59	50	—
Accounts payable	2	3	—	—	—
Accrued expenses	16	5	—	—	—
Lease liabilities, current	202,376	834,799	749,112	682,039	—
CIRM liability, current	6	0	—	—	—
Deferred revenue, current	12	12	24	18	30
TOTAL CURRENT LIABILITIES	36	21	31	24	—
CIRM liability, net of current	0	3	3	—	—
Lease liabilities, net of current	14	616,315	1	2	—
TOTAL LONG-TERM LIABILITIES	14	4	5	15	—
TOTAL LIABILITIES	50	25	36	38	—
COMMITMENTS AND CONTINGENCIES (NOTE 15)	—	—	—	—	—
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding	—	—	—	—	—
Common stock, $0.001 par value, 100,000,000 shares authorized, 57,370,909 and 45,582,288 shares issued and outstanding, respectively	57,371	45,582	31,148	25,241	—
Additional paid-in capital	610	344	182	149	—
Accumulated other comprehensive income	283,154	1	235,813	105,244	—
Accumulated deficit	−305	−200	−159	−137	—
TOTAL STOCKHOLDERS' EQUITY	306	145	23	12	—
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	356	170	59	50	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−105	−40	−22	−29	−20
Depreciation and amortization	2	1	1	533,131	245,697
Stock-based compensation	17	10	—	—	—
Restricted stock awards granted	257,461	0	—	—	—
Changes in lease liabilities	715,459	−47,261	−24,282	161,740	48,395
Receivables	10	3,504	−10	−155,830	−391,750
Prepaid expenses and other assets	−4	−458,653	−75,884	240,045	−148,728
Accounts payable and accrued expenses	6	2	1	2	400,750
Deferred revenue	0	−12	−3	27	0
Net cash used in operating activities	−70	−40	−26	5	−17
Purchase of marketable securities	−151	−208	−97	−114	0
Proceeds from sales and maturities of marketable securities	261	94	105	83	0
Purchases of property and equipment	−3	−1	−1	−2	−1
Payments for leasehold improvements	−383,539	−372,104	−735,873	−1	0
Payments for construction in progress	−8	0	—	—	—
Net cash provided by (used in) investing activities	97	−116	5	−35	−1
Net proceeds from sale of common stock	237	152	26	5	20
Proceeds from exercise of stock awards and warrants	12	450,173	64,601	70,304	50,562
Net cash provided by financing activities	249	153	26	5	20
Net increase (decrease) in cash and cash equivalents	277	−3	5	−25	2
Interest paid in cash	0	0	0	0	0
Income taxes paid in cash	1,600	1,600	0	0	0
Initial recognition of right-of-use asset	13	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro